As a key enterprise in Huaihai Biomedical Industrial Park, Professor Wang Hualiang and Professor Song Haibo and their entourage visited our company’s Xuzhou production base – Rocgene (Xuzhou) Scientific Instruments Co., Ltd., and listened to the introduction of the company’s development by General Manager Dai Tao. Mr. Dai stated that after successively obtaining CE-IVD, ISO13485, ISO9001 and NMPA medical device registration certificates, Rocgene has established a complete medical device production system and product certification system. As of that day, the 2022 annual orders had exceeded 200 million yuan, and the company was now in a critical production stage.

Rocgene (Xuzhou) Scientific Instruments Co., Ltd. is an enterprise located in Huaihai Biomedical Industrial Park. The production base covers an area of nearly 3,000 square meters, with nearly 2,000 square meters of workshops and supporting facilities built in accordance with national GMP standards. It has three professional production lines: real-time PCR instrument assembly, real-time PCR diagnostic reagent production, and automatic nucleic acid extractor assembly. Its products are widely used in various scenarios of clinical molecular diagnostics. Rocgene’s superior cost-performance ratio, reliable quality and professional services are deeply welcomed by customers. Especially during the COVID-19 pandemic, the whole company worked together to ensure production, which was highly recognized by the industrial park and relevant leaders.

As a core domestic supplier of real-time quantitative PCR systems, Rocgene will continue to increase investment in R&D and production, continuously optimize product quality, improve its product portfolio, actively participate in the construction of the park’s “Six Platforms and One Center” innovation system, support Xuzhou High-Tech Zone in building a world-class national high-tech zone, and promote the rapid development of China’s in vitro diagnostic industry.